ki 67 antigen

Summary

Summary: A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.

Top Publications

  1. ncbi The Ki-67 protein: from the known and the unknown
    T Scholzen
    Division of Molecular Immunology, Research Center Borstel, Germany
    J Cell Physiol 182:311-22. 2000
  2. ncbi Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions
    Michel R Nasr
    Department of Pathology, State University of New York Upstate Medical University, Syracuse, NY, USA
    Am J Dermatopathol 30:117-22. 2008
  3. pmc Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients
    E de Azambuja
    Medical Oncology Clinic, Jules Bordet Institute, 125 Boulevard de Waterloo, 1000, Brussels, Belgium
    Br J Cancer 96:1504-13. 2007
  4. ncbi Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients
    R Stuart-Harris
    Cancer Research UK Cambridge Research Institute, Department of Oncology, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Breast 17:323-34. 2008
  5. ncbi Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, 4th Floor, Wallace Wing, The Royal Marsden Hospital, Fulham Road, London SW3 6 JJ, UK
    J Natl Cancer Inst 99:167-70. 2007
  6. ncbi Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Via Ripamoniti 435, Milan, Italy
    J Natl Cancer Inst 100:207-12. 2008
  7. ncbi Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis
    R Bos
    Department of Pathology, Free University Hospital, Amsterdam, The Netherlands
    J Natl Cancer Inst 93:309-14. 2001
  8. ncbi Ki67 protein: the immaculate deception?
    D C Brown
    Department of Histopathology, Whittington Hospital, London, UK
    Histopathology 40:2-11. 2002
  9. ncbi Dissociation between steroid receptor expression and cell proliferation in the human breast
    R B Clarke
    Clinical Research Department, University of Manchester Christie Hospital National Health Service Trust, United Kingdom
    Cancer Res 57:4987-91. 1997
  10. ncbi Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?
    Helen Trihia
    International Breast Cancer Study Group Pathology Center, Western Infirmary, Glasgow, United Kingdom
    Cancer 97:1321-31. 2003

Research Grants

  1. IN-VITRO AND IN-VIVO EFFECTS OF GM-CSF ON ADULT ANLL
    Camille Abboud; Fiscal Year: 1992
  2. H PYLORI PHENOTYPE AND STOMACH CANCER
    Atsuko Shibata; Fiscal Year: 2000
  3. Lung Cancer Prognosis: FLT PET and DNA Hypermethylation
    Hubert Vesselle; Fiscal Year: 2009
  4. FLT PET to Plan the Best Therapy for Lung Cancer
    Hubert Vesselle; Fiscal Year: 2008
  5. MR Dynamic Imaging and Spectroscopy in Head & Neck Cancers
    AMITA DAVE; Fiscal Year: 2010
  6. THE BIOLOGY OF LUNG CANCER-- FDG AND FLUOROTHYMIDINE PET
    Hubert Vesselle; Fiscal Year: 2004
  7. Diet, Obesity and Stress
    Yvonne Ulrich Lai; Fiscal Year: 2005
  8. Functional Aspects of Adult Hippocampal Neurogenesis
    JULIAN KEITH; Fiscal Year: 2007
  9. Xenogen IVIS-200 Bioluminescent Imaging System
    Alan Pollack; Fiscal Year: 2007
  10. Ethanol, neurotrophins, and thalamocortical matching
    SANDRA MOONEY; Fiscal Year: 2006

Detail Information

Publications259 found, 100 shown here

  1. ncbi The Ki-67 protein: from the known and the unknown
    T Scholzen
    Division of Molecular Immunology, Research Center Borstel, Germany
    J Cell Physiol 182:311-22. 2000
    ..There are indications, however, that Ki-67 protein expression is an absolute requirement for progression through the cell-division cycle...
  2. ncbi Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions
    Michel R Nasr
    Department of Pathology, State University of New York Upstate Medical University, Syracuse, NY, USA
    Am J Dermatopathol 30:117-22. 2008
    ..pHH3 and Ki-67 can be useful adjuncts to histopathology to separate malignant melanoma from benign nevi. pHH3 is especially useful to highlight mitoses and to rapidly assess the mitotic activity in melanocytic lesions...
  3. pmc Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients
    E de Azambuja
    Medical Oncology Clinic, Jules Bordet Institute, 125 Boulevard de Waterloo, 1000, Brussels, Belgium
    Br J Cancer 96:1504-13. 2007
    ..65-3.91); P<0.001) and node-positive patients (HR=2.33 (95% CI: 1.83-2.95); P<0.001). Our meta-analysis suggests that Ki-67/MIB-1 positivity confers a higher risk of relapse and a worse survival in patients with early BC...
  4. ncbi Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients
    R Stuart-Harris
    Cancer Research UK Cambridge Research Institute, Department of Oncology, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Breast 17:323-34. 2008
    ..Ki-67, MI, PCNA and LI are associated with worse survival outcomes in early breast cancer. However, whether these proliferation markers provide additional prognostic information to commonly used prognostic indices remains unclear...
  5. ncbi Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, 4th Floor, Wallace Wing, The Royal Marsden Hospital, Fulham Road, London SW3 6 JJ, UK
    J Natl Cancer Inst 99:167-70. 2007
    ....
  6. ncbi Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Via Ripamoniti 435, Milan, Italy
    J Natl Cancer Inst 100:207-12. 2008
    ..Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies...
  7. ncbi Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis
    R Bos
    Department of Pathology, Free University Hospital, Amsterdam, The Netherlands
    J Natl Cancer Inst 93:309-14. 2001
    ..Increased levels of HIF-1 alpha are associated with increased proliferation and increased expression of ER and VEGF. Thus, increased levels of HIF-1 alpha are potentially associated with more aggressive tumors...
  8. ncbi Ki67 protein: the immaculate deception?
    D C Brown
    Department of Histopathology, Whittington Hospital, London, UK
    Histopathology 40:2-11. 2002
    ..This review attempts to provide an update on the characterization of the Ki67 protein, its function and its use as a prognostic or diagnostic tool...
  9. ncbi Dissociation between steroid receptor expression and cell proliferation in the human breast
    R B Clarke
    Clinical Research Department, University of Manchester Christie Hospital National Health Service Trust, United Kingdom
    Cancer Res 57:4987-91. 1997
    ..This organization may be disrupted in some tumors...
  10. ncbi Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?
    Helen Trihia
    International Breast Cancer Study Group Pathology Center, Western Infirmary, Glasgow, United Kingdom
    Cancer 97:1321-31. 2003
    ..The Ki-67 nuclear antigen may be considered as an alternative to mitotic counts in grading schemes and as a single parameter that can be used in fine-needle aspirates and small biopsies...
  11. ncbi Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods
    Federico Ambrogi
    Unit of Medical Statistics and Biometry, National Cancer Institute of Milano, Milan, Italy
    Clin Cancer Res 12:781-90. 2006
    ..Thus, we sought to identify distinct tumor profiles with possible clinical relevance based on clusters of immunohistochemical molecular markers measured on a large, single institution, case series...
  12. ncbi Vascular supply as a discriminating factor for pig preantral follicle selection
    A Martelli
    Department of Comparative Biomedical Sciences, University of Teramo, Teramo, Italy
    Reproduction 137:45-58. 2009
    ..The follicles with this high activity are probably able to reach class 6 becoming dominant structures where somatic and vascular parameters are constantly on high levels and the VA remains the unique differentiating element...
  13. pmc Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival
    A Giatromanolaki
    Department of Pathology, Democritus University of Thrace, P O Box 128, Alexandroupolis 68100, Greece
    Br J Cancer 85:881-90. 2001
    ..Targeting the HIF pathway may prove of importance in the treatment of NSCLC...
  14. pmc Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma
    A E Pinto
    , , , Centro de Lisboa, 1099-023 Lisboa Codex, Portugal
    J Clin Pathol 54:543-9. 2001
    ..3844; p < 0.001), especially in the subgroup of diploid tumours. CONCLUSIONS: Flow cytometric SPF is a better prognosticator than the Ki-67 index, but only SPF variables applied in the whole series show potential clinical usefulness...
  15. ncbi Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors
    P Roger
    Laboratoire de Biologie Cellulaire et Hormonale, H pital Arnaud-de-Villeneuve, Montpellier, France
    Cancer Res 61:2537-41. 2001
    ..Knowledge of the ERbeta and ERalpha content in each preinvasive lesion should help to rationalize antiestrogen preventive therapy adapted to each individual patient...
  16. ncbi Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death
    Puay Hoon Tan
    Department of Pathology, Singapore General Hospital, Singapore
    Mod Pathol 18:374-81. 2005
    ..Differential regulation of these genes, especially bcl2, may contribute to the biological nature of clinically more aggressive and highly proliferative breast cancers...
  17. pmc Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer
    Hiroko Yamashita
    Breast and Endocrine Surgery, Nagoya City University Hospital, Nagoya, Japan
    Breast Cancer Res 6:R24-30. 2004
    ..Although the available studies suggest that these factors might indeed be helpful in making treatment decisions in cancer patients, their clinical usefulness is still controversial...
  18. pmc Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome
    I F Faneyte
    Department of Pathology, The Netherlands Cancer Institute, Amsterdam
    Br J Cancer 88:406-12. 2003
    ..Proliferation decreases significantly after chemotherapy. ER negativity and a high proliferation index are associated with better response. HER2 status does not predict response, and outcome is not related to tumour response...
  19. pmc Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival
    S E Pinder
    Department of Histopathology, City Hospital, Nottingham, UK
    Br J Cancer 71:146-9. 1995
    ..The results suggest that the tumour growth fraction, as assessed by the MIB1 labelling index, is an important predictor of survival...
  20. pmc MIB-1 labelling index is an independent prognostic marker in primary breast cancer
    R L Jansen
    Department of Internal Medicine, University Hospital Maastricht, The Netherlands
    Br J Cancer 78:460-5. 1998
    ..08). Thus, in conclusion, the growth fraction of a tumour as determined by the MIB-1 labelling index is an important prognostic factor in patients with primary breast cancer...
  21. ncbi Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods
    Laura M Kenny
    Molecular Therapy and PET Oncology Research Group, Hammersmith Hospital, London, UK
    Cancer Res 65:10104-12. 2005
    ..We conclude that [18F]FLT-positron emission tomography is a promising clinical tool for imaging cellular proliferation in breast cancer, and is most predictive when analyzed by graphical and spectral methods...
  22. ncbi Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value
    Frederique Spyratos
    Laboratoire d Oncobiologie, Centre Rene Huguenin, Saint Cloud, France
    Cancer 94:2151-9. 2002
    ..The objectives of this study were to compare MIB-1 evaluation to other methods of measuring cell proliferation, with a view to refining the cutoff used to classify tumors with low and high proliferation rates in therapeutic trials...
  23. ncbi Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy
    Qifeng Yang
    Department of General Surgery, Qilu Hospital, Shandong University, Ji Nan, Shandong Province, PR China
    Oncol Rep 10:121-5. 2003
    ..0242) after consideration of other prognostic factors. Our results imply that Bcl-2 is a significant favorable prognostic factor for breast cancer with chemotherapy and endocrine therapy...
  24. ncbi FANCD2 protein is expressed in proliferating cells of human tissues that are cancer-prone in Fanconi anaemia
    Michael Hölzel
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    J Pathol 201:198-203. 2003
    ..FANCD2 expression is frequently expressed in proliferating cells as demonstrated by Ki-67 immunofluorescence double staining, consistent with a function of FANCD2 in DNA replication...
  25. ncbi Influence of maternal diabetes on placental fibroblast growth factor-2 expression, proliferation, and apoptosis
    D W Burleigh
    Wisconsin National Primate Research Center, University of Wisconsin, Madison, Wisconsin, USA
    J Soc Gynecol Investig 11:36-41. 2004
    ..Alteration of placental development in women with diabetes may contribute to the increased risk of preeclampsia, macrosomia, or fetal growth restriction...
  26. ncbi Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10
    Rile Li
    Department of Pathology, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 10:4118-24. 2004
    ..In a prior study, we found that a Ki-67 SI of >3.5% was associated with poorer patient outcome. The goals of this analysis were to validate the prognostic value of Ki-67 SI and this cut point...
  27. ncbi Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index
    P Jalava
    Department of Pathology, University of Turku, Turku, Finland
    Histopathology 48:674-82. 2006
    ..The aim of this study was to investigate this more closely and also to study the associations between bcl-2 and p53 expression and proliferation...
  28. pmc Expression of p27(KIP1) and cyclin D1, and cell proliferation in human pterygium
    Satoru Kase
    Department of Ophthalmology, Sapporo Social Insurance General Hospital, Sapporo, Japan
    Br J Ophthalmol 91:958-61. 2007
    ..The pterygium is a growth onto the cornea of fibrovascular tissue that is continuous with the conjunctiva, whereas the mechanisms of cell proliferation in pterygium epithelium are unknown...
  29. ncbi Correlation of proliferative markers (Ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients
    H Myoung
    Department of Oral and Maxillofacial Surgery and Dental Research Institute, College of Dentistry, Seoul National University, Korea
    Int J Oral Maxillofac Surg 35:1005-10. 2006
    ..From this result, it can be postulated that the cancer staging based on the TNM stage was a powerful prognostic variable and Ki-67 had a significant effect on the cumulative survival rate...
  30. ncbi Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response
    Robin L Jones
    Breast Unit, Royal Marsden Hospital, London, UK
    Lancet Oncol 7:869-74. 2006
    ..In addition, the anatomical accessibility of the breast provides the potential for serial biopsies to investigate molecular changes during treatment...
  31. pmc Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence
    E A Griffiths
    Academic Radiation Oncology, Division of Cancer Studies, Christie Hospital, The University of Manchester, Wilmslow Road, Withington, Manchester M20 4BX, UK
    Br J Cancer 96:1377-83. 2007
    ..The late expression of HIF-2alpha in the Barrett's carcinogenesis sequence and its high expression in adenocarcinoma suggest that it is worth further investigation as a marker of disease progression and therapeutic target...
  32. ncbi Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma
    Roland Ullrich
    Max Planck Institute for Neurological Research with Klaus Joachim Zülch Laboratories, Cologne, Germany
    Clin Cancer Res 14:2049-55. 2008
    ....
  33. ncbi The Ki-67 protein: fascinating forms and an unknown function
    E Endl
    Department of Immunology and Cell Biology, Research Center Borstel, Borstel, D 23845, Germany
    Exp Cell Res 257:231-7. 2000
    ..The recently published data add new pieces to the challenging puzzle of this multifaceted protein, which are waiting to be put together...
  34. ncbi A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: implications for the prediction of outcome in colorectal cancer
    Ian S Scott
    MRC Cancer Cell Unit, Hutchison MRC Research Centre, Hills Road, Cambridge, CB2 2XZ, UK
    J Pathol 201:187-97. 2003
    ..Detectable cyclin A can be used as a surrogate marker of S phase and may be of value in predicting prognosis and response to adjuvant therapy...
  35. ncbi A candidate precursor to serous carcinoma that originates in the distal fallopian tube
    Y Lee
    Division of Women s and Perinatal Pathology, Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Pathol 211:26-35. 2007
    ....
  36. ncbi Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach
    N A C S Wong
    Department of Pathology, University of Edinburgh Medical School, Edinburgh, UK
    Histopathology 43:118-26. 2003
    ..Our aim was to test previously studied and more novel morphological features as well as four immunohistochemical markers as prognostic indicators amongst a large cohort of surgically resected, gastric GISTs...
  37. ncbi DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas
    K Iino
    Department of Pathology, Tohoku University School of Medicine, Sendai, Japan
    Mod Pathol 10:901-7. 1997
    ..This indicates that immunohistochemical analysis of Ki-67 and topoII alpha could help to differentiate carcinoma from adenoma in resected adrenocortical neoplasms and might predict aggressive biologic behavior in carcinomas...
  38. ncbi Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study
    Mariagiovanna Filippella
    Department of Endocrinology and Reproductive Diseases, Assistance Publique Hopitaux de Paris, Hopital de Bicetre, France
    Clin Endocrinol (Oxf) 65:536-43. 2006
    ....
  39. ncbi Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer
    J F Robertson
    Department of Surgery, Nottingham City Hospital, Nottingham, United Kingdom
    Cancer Res 61:6739-46. 2001
    ..Reductions in tumor cell proliferative activity (as indicated by Ki67LI) show that ICI 182,780 is likely to have antitumor activity in the clinical setting...
  40. pmc Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis
    B Martin
    Critical Care Department and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Brussels, Belgium
    Br J Cancer 91:2018-25. 2004
    ..56 (95% CI: 1.30-1.87), showing a worse survival when Ki-67 expression is increased. In conclusion, our meta-analysis shows that the expression of Ki-67 is a factor of poor prognosis for survival in NSCLC...
  41. ncbi Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group
    Olaf Determann
    Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    Blood 111:2385-7. 2008
    ..013). Thus, the Ki-67 index remains an important prognostic marker in the era of anti-CD20 therapy. The Euro-pean MCL study is registered at www.ClinicalTrials.gov as #NCT00016887...
  42. ncbi Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland
    J Russo
    Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Breast Cancer Res Treat 53:217-27. 1999
    ....
  43. ncbi Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma
    Phyllis A Gimotty
    Melanoma Program of the Abramson Cancer Center, Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
    J Clin Oncol 23:8048-56. 2005
    ..In this study, we characterized three biomarkers of proliferation (Ki67 expression, dermal mitotic rate [MR], and tumorigenicity) in thin (< or = 1.00 mm) primary cutaneous melanomas and examined their association with prognosis...
  44. ncbi Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients
    Nicolaus Kroger
    Department of Bone Marrow Transplantation, Transplant Center, Hamburg Eppendorf, Hamburg, Germany
    Clin Cancer Res 12:159-68. 2006
    ..To analyze prognostic and predictive effects of immunohistochemical factors within a randomized study of high-dose versus standard-dose chemotherapy in high-risk breast cancer with >10 involved lymph nodes...
  45. ncbi EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast
    Ingeborg M Bachmann
    Gade Institute, Section of Pathology, Bergen, Norway
    J Clin Oncol 24:268-73. 2006
    ..The purpose of this study was to validate previous findings in a population-based setting, also including tumors that have not been studied previously...
  46. ncbi Lymphatic spread is related to VEGF-C expression and D2-40-positive myofibroblasts in intrahepatic cholangiocarcinoma
    Shinichi Aishima
    Department of Pathology, Hamanomachi Hospital, Fukuoka, Japan
    Mod Pathol 21:256-64. 2008
    ..D2-40-positive myofibroblasts may contribute to lymphatic metastasis...
  47. ncbi Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden
    Bengt Nilsson
    Department of Surgery, The Lundberg Laboratory for Cancer Research, Sahlgrenska Academy at the University of Göteborg, Goteborg, Sweden
    Cancer 103:821-9. 2005
    ..New treatment options mandate more accurate information regarding the incidence, prevalence, clinical behavior, and prognostic factors of GIST...
  48. ncbi Prognostic relevance of cell proliferation in head and neck tumors
    A Pich
    Department of Biomedical Sciences and Human Oncology, Section of Pathology, University of Turin, Italy
    Ann Oncol 15:1319-29. 2004
    ..Provided that large and homogeneous series are evaluated by standardized methods, cell proliferative activity can still be regarded as an inexpensive and reliable prognostic factor in head and neck tumors...
  49. ncbi Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index
    Grace M Callagy
    Cancer Genomics Program, Department of Oncology, Hutchison Medical Research Council Research Centre, University of Cambridge, United Kingdom
    Clin Cancer Res 12:2468-75. 2006
    ..We validated the results in an independent series...
  50. ncbi Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer
    Michael A Gonzalez
    Medical Research Council Cancer Cell Unit, Hutchison Medical Research Council Research Centre, Hills Rd, Cambridge CB2 2XZ, United Kingdom
    J Clin Oncol 21:4306-13. 2003
    ..To test the hypothesis that prognostic information in breast cancer may be derived from an accurate assessment of epithelial cell cycle entry, as indicated by expression of minichromosome maintenance (MCM) proteins...
  51. ncbi Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer
    L Assersohn
    Breast Unit, Royal Marsden Hospital, Sutton, Surrey, UK
    Breast Cancer Res Treat 82:113-23. 2003
    ..Objectives were to characterise the relationship of the proliferation marker Ki67 with response to systemic treatment in early breast cancer and to assess its clinical utility, using fine needle aspirates...
  52. pmc Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer
    A Bottini
    Centro di Senologia, Azienda Ospedaliera Istituti Ospitalieri, Viale Concordia 1, Cremona, 26100, Italy
    Br J Cancer 85:1106-12. 2001
    ..Reduction in Ki67 immunostaining correlated with clinical response but failed to be related to RFS. Ki67 expression at surgery rather than at baseline appears to be a better predictor for disease relapse...
  53. ncbi Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53
    M Feith
    Chriurgische Klinik und Poliklinik der Technischen Universität München, Germany
    Dis Esophagus 17:322-7. 2004
    ..This might aid in the early detection of esophageal adenocarcinoma...
  54. pmc Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa
    J J Going
    Department of Pathology, Glasgow University, Glasgow Royal Infirmary, Glasgow, UK
    Gut 50:373-7. 2002
    ..Expression is dysregulated in dysplastic states but data for oesophageal squamous mucosa and Barrett's mucosa have not been published...
  55. pmc Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomas
    I R K Bukholm
    Department of Surgery, Akershus University Hospital, 1474 Nordbyhagen, Norway
    J Clin Pathol 56:368-73. 2003
    ....
  56. pmc Improved cervical smear assessment using antibodies against proteins that regulate DNA replication
    G H Williams
    Wellcome Trust Cancer Research Campaign Institute, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QR, United Kingdom
    Proc Natl Acad Sci U S A 95:14932-7. 1998
    ..Thus antibodies against proteins that regulate DNA replication can reduce the high false-negative rate of the Pap smear test and may facilitate mass automated screening...
  57. ncbi Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)
    D De Jong
    Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Clin Pathol 62:128-38. 2009
    ..In this study, an international collaboration of clinical lymphoma research groups has concentrated on validation and standardisation of immunohistochemistry of the currently potentially interesting prognostic markers in DLBCL...
  58. ncbi Immunohistochemical characteristics of melanoma
    Steven J Ohsie
    Department of Pathology and Laboratory Medicine, Geffen UCLA School of Medicine, Los Angeles, CA 90095 1732, USA
    J Cutan Pathol 35:433-44. 2008
    ..Ki67 remains the most useful adjunct in distinguishing benign from malignant melanocytic tumors. None of the markers reviewed has been shown conclusively to have prognostic value for melanocytic neoplasms...
  59. ncbi Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas
    Maria Niveiro
    Department of Pathology, General Universitary Hospital of Alicante, Pintor Baeza s n, 03010 Alicante, Spain
    Hum Pathol 36:1090-5. 2005
    ..Moreover, Flk-1 is associated with a more aggressive phenotype, and it may have potential therapeutic interest...
  60. ncbi p27 Labeling index and proliferation in gastrointestinal stromal tumors: correlations with clinicopathologic factors and recurrence
    Tekinalp Gelen
    Department of Pathology, Akdeniz University, Medical School, Antalya, Turkey
    Jpn J Clin Oncol 33:346-52. 2003
    ....
  61. ncbi Cell division and cleavage orientation in the developing retina are regulated by L-DOPA
    Marc S Tibber
    Institute of Ophthalmology, University College London, UK
    J Comp Neurol 496:369-81. 2006
    ..J. Comp. Neurol. 496:369-381, 2006. (c) 2006 Wiley-Liss, Inc...
  62. ncbi Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer
    Karin Collett
    Section for Pathology, The Gade Institute, Haukeland University Hospital, Norway
    Clin Cancer Res 12:1168-74. 2006
    ..These findings might be practically important and relevant because the polycomb group proteins have recently been suggested as candidates for targeted therapy...
  63. ncbi Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry and Breast Unit, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    Clin Cancer Res 12:1024s-1030s. 2006
    ..We argue that these changes in proliferation and concurrent changes in apoptosis may be expected to be more predictive of adjuvant benefit from endocrine therapy than clinical response...
  64. ncbi Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
    M Colozza
    S C Oncologia Medica, Azienda Ospedaliera, San Sisto 06132 Perugia, Italy
    Ann Oncol 16:1723-39. 2005
    ..Early incorporation of translational research and new technologies with clinical trials are needed to prospectively validate biological markers and allow their use in clinical practice...
  65. ncbi Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study
    Kyoichi Kaira
    Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
    Clin Cancer Res 13:6369-78. 2007
    ..Tumor uptake of [(18)F]FMT was compared with that of 2-[(18)F]-fluoro-2-deoxy-D-glucose ([(18)F]FDG) and correlated with L-type amino acid transporter 1 (LAT1) expression...
  66. ncbi Primary resected meningiomas: relapses and proliferation markers
    Jean Pierre Kalala
    Department of Neurosurgery, University Hospital, De Pintelaan 185, Ghent, Belgium
    In Vivo 18:411-6. 2004
    ..Relapses of meningiomas are a well known phenomenon during follow-up. The significance of sex, age, surgical treatment and mitotic frequency with regard to relapses are still a matter of debate...
  67. ncbi Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment
    Marco Colleoni
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Cancer Res 10:6622-8. 2004
    ..The purpose of this research was to identify factors predicting response to preoperative chemotherapy...
  68. ncbi Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas
    Yoo Jin Kim
    Institute of Neuropathology, Saarland University, School of Medicine, Homburg Saar, Germany
    Am J Clin Pathol 128:118-25. 2007
    ..In contrast with the Ki-67 LI, H&E MI and PHH3 MI also remained as independent predictors in the multivariate Cox hazards modeling (P = .0007 and P = .0004, respectively)...
  69. pmc Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma
    C Schrader
    Second Department of Internal Medicine and Hematology, University Hospital of Schleswig Holstein, Campus Kiel, Chemnitzstr 33, 24116 Kiel, Germany
    Br J Cancer 93:939-45. 2005
    ..Therefore, aside from gene expression profiling, immunohistochemical detection of MCM6 seems to be the most promising marker for predicting the outcome in MCL...
  70. ncbi Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London
    Clin Cancer Res 11:951s-8s. 2005
    ....
  71. ncbi Role of PTEN in gastrointestinal stromal tumor progression
    Riccardo Ricci
    Department of Pathology, Universita Cattolica del Sacro Cuore, Universita Cattolica, Rome, Italy
    Arch Pathol Lab Med 128:421-5. 2004
    ....
  72. pmc Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67
    J Gerdes
    Division of Molecular Immunology, Forschungsinstitut Borstel, Federal Republic of Germany
    Am J Pathol 138:867-73. 1991
    ..This cDNA fragment could be bacterially expressed, and in subsequent immunoblot analysis Ki-67 reacted exclusively with those fusion proteins that were derived from bacteria containing the insert in the right reading frame...
  73. ncbi Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours
    T Seidal
    Department of Pathology, Karlstad, Central Hospital, Sweden
    Histopathology 34:416-24. 1999
    ..Furthermore, the aim was to correlate clinical, histological and immunophenotypic parameters to their clinical course by means of statistical analysis...
  74. ncbi Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia
    J T Keating
    Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Surg Pathol 25:884-91. 2001
    ....
  75. ncbi Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis
    S S Li
    Department of Pathology, School of Medicine, Zhengzhou University, Zhengzhou, China
    Histopathology 46:307-13. 2005
    ..MCM proteins are essential for eukaryotic DNA replication and have recently been used to define the proliferative compartments in human tissues...
  76. pmc Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer
    C D Archer
    Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 89:1035-41. 2003
    ..Pretreatment proliferation and GI are however predictive of response to chemotherapy in breast cancer...
  77. ncbi Prognostic value of MCM2 immunoreactivity in stage T1 transitional cell carcinoma of the bladder
    Stefan Kruger
    Institute of Pathology, University of Lubeck, Ratzeburger Allee 160, D 23538, Lubeck, Germany
    Eur Urol 43:138-45. 2003
    ..To our knowledge, there are no reports on studies investigating minichromosome maintenance protein 2 (MCM2) expression in bladder carcinomas. Thus, we investigated the prognostic value of MCM2 immunoreactivity in stage T1 bladder tumors...
  78. pmc Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: the FLiMP mouse model
    Uddhav P Kelavkar
    Department of Urology and Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
    Neoplasia 8:510-22. 2006
    ..The FLiMP mouse model should also be useful in crosses with other GEM models to further define the combinations of molecular alterations necessary for PCa progression...
  79. ncbi High proliferative activity may predict early metastasis of thin melanomas
    S O Frahm
    Department of Pathology, University of Kiel, Germany
    Hum Pathol 32:1376-81. 2001
    ..Further investigations are needed to determine the value of proliferation measurements for the long-term prognosis of thin melanomas...
  80. pmc Prognostic value of Ki-67 immunolabelling in primary operable breast cancer
    M Railo
    Helsinki University Central Hospital, Finland
    Br J Cancer 68:579-83. 1993
    ..02), tumour size (P < 0.0001) and nodal status (P < 0.006) were independent prognostic factors. We conclude that the potential value of Ki-67 labelling for prognostic evaluation of patients with breast carcinoma is good...
  81. ncbi Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value
    M A Heesters
    Department of Radiotherapy, Groningen University Hospital, The Netherlands
    J Neurooncol 44:255-66. 1999
    ..MIB-LI is of independent prognostic value in A and AA. Assessment of MIB-LI in A and AA can be used as an aid in distinguishing A and AA...
  82. pmc Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
    R J Burcombe
    Academic Oncology Unit, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK
    Br J Cancer 92:147-55. 2005
    ..1% after treatment (P = 0.02); the median reduction in Ki-67 index after treatment was 21.2%. Tumours displaying >75% reduction in Ki-67 after chemotherapy were more likely to achieve a pathological response (77.8 vs 26.7%, P = 0.004)...
  83. ncbi Changes in the topological expression of markers of differentiation and apoptosis in defined stages of human cervical dysplasia and carcinoma
    Silvia Zanotti
    Department of Anatomy and Embryology, Ruhr Universitat, Bochum, Germany
    Gynecol Oncol 89:376-84. 2003
    ..We compared the capacity of cells in normal cervical epithelium, progressive stages of CIN, and invasive carcinoma to proliferate, differentiate, and undergo apoptosis...
  84. ncbi Combined analysis of MIB-1 and thyroid transcription factor-1 predicts survival in non-small cell lung carcinomas
    F Puglisi
    Department of Clinical Oncology, University of Udine, Piazzale SM Misericordia, 33100, Udine, Italy
    Cancer Lett 162:97-103. 2001
    ..002), MIB-1 (P=0.01) and pStage (P=0.04). Accordingly, analysing TTF-1 and MIB-1 together, a better prediction of survival was obtained (P=0.02), with the poorest prognosis for the 'TTF-1++/MIB-1+' cases...
  85. ncbi MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer
    N Ramnath
    Lung Cancer Program, Roswell Park Cancer Institute, Buffalo, NY, USA
    J Clin Oncol 19:4259-66. 2001
    ..Whether MCM2 is predictive of response to therapy needs to be studied...
  86. ncbi Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma
    Donald Ming Tak Ho
    Department of Pathology and Laboratory Medicine, Veterans General Hospital Taipei, Taipei, Taiwan, Republic of China
    Cancer 94:1538-47. 2002
    ..The objective of this study was to formulate diagnostic criteria for atypical meningioma...
  87. ncbi Apoptosis and cell proliferation in the development of gastric carcinomas: associations with c-myc and p53 protein expression
    Hideaki H Ishii
    Second Department of Pathology, Tokyo Medical University, Japan
    J Gastroenterol Hepatol 17:966-72. 2002
    ..The aim of the present paper was to characterize cellular and molecular properties to provide insight into aspects of tumor progression in early compared with advanced gastric cancers...
  88. ncbi The expression of Ki-67, MCM3, and p27 defines distinct subsets of proliferating, resting, and differentiated cells
    E Endl
    Department of Immunology and Cell Biology, Division of Molecular Immunology, Research Center Borstel, D 23845 Borstel, Germany
    J Pathol 195:457-62. 2001
    ..In conclusion, a combined analysis of Ki-67, MCM3, and p27 protein expression may provide a more detailed insight into the cell proliferation and differentiation processes that determine individual tumour growth...
  89. pmc Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity
    H J van Slooten
    Department of Surgery, Leiden University Medical Centre, The Netherlands
    Br J Cancer 77:789-96. 1998
    ....
  90. pmc Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer
    G Gasparini
    St Bortolo Regional Hospital, USSL 8 Vicenza Veneto, Italy
    Br J Cancer 66:970-6. 1992
    ....
  91. ncbi Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma
    Oddbjørn Straume
    Department of Pathology, The Gade Institute, University of Bergen, N 5021 Bergen, Norway
    Clin Cancer Res 9:250-6. 2003
    ..In addition, our data suggest the presence of low-grade intra-tumoral lymphangiogenesis in melanoma and a stimulating role of bFGF in lymphangiogenesis...
  92. pmc Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study
    Eric D Hsi
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
    Leuk Lymphoma 49:2081-90. 2008
    ..High Ki67 (>35%) is an important independent prognostic marker in aggressively treated MCL in the rituximab era. PIM1 expression predicts poor outcome and, given its potential role as a therapeutic target, deserves further study...
  93. pmc Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 26:5569-75. 2008
    ..To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy in postmenopausal women with early breast cancer...
  94. ncbi A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas
    M L Jaffrain-Rea
    Department of Experimental Medicine, Universita degli Studi di L Aquila, Via Vetoio, Coppito 2, 67100 L Aquila AQ, Italy
    Endocr Relat Cancer 9:103-13. 2002
    ..LI should be interpreted according to hormone secretion and pre-operative treatment. Unusually high LI values deserve particular attention...
  95. ncbi Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer
    A M Billgren
    Department of Oncology and Pathology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Breast Cancer Res Treat 71:161-70. 2002
    ..To our knowledge, this is the first study demonstrating PF, which can contribute prognostic information when analyzed in preoperative smears...
  96. ncbi Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma
    N Rioux-Leclercq
    Department of Pathology, Johns Hopkins Hospital, Baltimore, MD, USA
    Hum Pathol 32:1209-15. 2001
    ..Cell proliferation and CD44H expression appear to be powerful markers to identify patients with an adverse prognosis...
  97. ncbi Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer
    Alberto Bottini
    Breast Cancer Unit, Azienda Ospedaliera Istituti Ospitalieri, Cremona, Italy
    Clin Cancer Res 8:1816-21. 2002
    ..The impact of chemotherapy +/- endocrine therapy on the extent of angiogenesis is unknown...
  98. ncbi Biological prognostic factors for early stage completely resected non-small cell lung cancer
    L Cagini
    Department of Surgical Sciences, University Hospital, Perugia, Italy
    J Surg Oncol 74:53-60. 2000
    ..Our study investigated the frequency of expression and the clinicopathologic and prognostic significance of a series of biological markers in stage I and II resected non-small cell lung cancer...
  99. ncbi Proliferation marker Ki-67 in early breast cancer
    Ander Urruticoechea
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    J Clin Oncol 23:7212-20. 2005
    ..However, its application as a pharmacodynamic intermediate marker of the effectiveness of medical therapy holds great promise for rapid evaluation of new drugs...
  100. ncbi Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis
    T J Cummings
    Duke University Medical Center, Department of Pathology, Durham, NC 27710, USA
    Acta Neuropathol 99:563-70. 2000
    ....
  101. pmc Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
    Kyung Hun Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 7:63. 2007
    ....

Research Grants64

  1. IN-VITRO AND IN-VIVO EFFECTS OF GM-CSF ON ADULT ANLL
    Camille Abboud; Fiscal Year: 1992
    ....
  2. H PYLORI PHENOTYPE AND STOMACH CANCER
    Atsuko Shibata; Fiscal Year: 2000
    ..p53 mutation (frequency and spectrum), cell proliferation and apoptotic indices will be compared according to the cagA status and histologic type of the cancer. ..
  3. Lung Cancer Prognosis: FLT PET and DNA Hypermethylation
    Hubert Vesselle; Fiscal Year: 2009
    ..This prognostic information will permit individualization and optimization of therapy for the 41,000 early stage NSCLC patients undergoing surgical resection each year in the United States. ..
  4. FLT PET to Plan the Best Therapy for Lung Cancer
    Hubert Vesselle; Fiscal Year: 2008
    ..At the conclusion of this study, the insight gained in the response of stage III NSCLCs will allow clinicians to plan the best therapy for these patients. [unreadable] [unreadable]..
  5. MR Dynamic Imaging and Spectroscopy in Head & Neck Cancers
    AMITA DAVE; Fiscal Year: 2010
    ..If successful, it will provide an a priori predictor of failure/response to chemotherapy and/or long term disease free-survival, resulting in patient specific treatment which will likely enhance outcome. ..
  6. THE BIOLOGY OF LUNG CANCER-- FDG AND FLUOROTHYMIDINE PET
    Hubert Vesselle; Fiscal Year: 2004
    ..By performing a biologic grading of resectable NSCLC with FDG PET, we will predict which patients will have a worse outcome. This information will allow individualized therapy. ..
  7. Diet, Obesity and Stress
    Yvonne Ulrich Lai; Fiscal Year: 2005
    ..abstract_text> ..
  8. Functional Aspects of Adult Hippocampal Neurogenesis
    JULIAN KEITH; Fiscal Year: 2007
    ..abstract_text> ..
  9. Xenogen IVIS-200 Bioluminescent Imaging System
    Alan Pollack; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  10. Ethanol, neurotrophins, and thalamocortical matching
    SANDRA MOONEY; Fiscal Year: 2006
    ..abstract_text> ..
  11. ROLE OF THE FAS ANTIGEN IN OVARIAN CELL APOPTOSIS
    SUSAN QUIRK; Fiscal Year: 2004
    ..Understanding pathways that promote or prevent susceptibility of ovarian cells to apoptosis may lead to development of novel therapies for ovarian and other cancers. ..
  12. The Roles of Osteonectin and Osteoactivin in Gliomas
    Jeremy Rich; Fiscal Year: 2007
    ..2) Validate osteonectin and osteoactivin as potential therapeutic targets in glioma invasion. It is hoped that these studies will provide the basis of novel therapeutic interventions for patients with malignant gliomas. ..
  13. GENETIC EPIDEMIOLOGY AND MECHANISMS IN ORAL CANCER
    Elaine Smith; Fiscal Year: 2003
    ..abstract_text> ..
  14. POLYAMINE INVOLVEMENT IN MAMMARY CARCINOGENESIS
    Andrea Manni; Fiscal Year: 2001
    ....
  15. Cell Differentation During Decidualization
    Zuzana Strakova; Fiscal Year: 2010
    ..Thus, in the long term our studies might provide new targets of intervention leading to improvements in diagnosis and treatment. ..
  16. STATs as a Novel Approach to Cancer Therapy
    James Turkson; Fiscal Year: 2009
    ..The proposed studies will refine and further develop lead compounds as potent Stat3 inhibitors with antitumor activities for eventual clinical applications ..
  17. Cs-137 Irradiator for new Fitzsimons Campus
    David Raben; Fiscal Year: 2007
    ..The JL 81 irradiator is an important component of this foundation of cancer research and will facilitate the preclinical experiments necessary for translation at the new UCDHSC Fitzsimons campus. [unreadable] [unreadable] [unreadable]..
  18. Breast Cancer Prevention by Letrozole in High Risk Women
    Carol J Fabian; Fiscal Year: 2010
    ....
  19. Coupling of 5-HT Receptors to Neuroprotective Pathways
    DANIEL COWEN; Fiscal Year: 2007
    ..Slices will be very helpful in interpreting the cause of observed lags in effect since autoreceptors are not present in cultured slices. [unreadable] [unreadable] [unreadable]..
  20. FlaxSeed Lignan for Breast Cancer Chemoprevention
    CAROL FABIAN; Fiscal Year: 2007
    ..If positive, the results of this study will be critical to the design and implementation of a placebo-controlled Phase II prevention trial with Brevail and/or commercial flaxseed. [unreadable] [unreadable]..
  21. MICROARRAY ANALYSIS OF RETINAL DEGENERATION IN MICE
    Caroline Zeiss; Fiscal Year: 2007
    ..Colin Barnstable, Professor of Neurobiology and Ophthalmology, who is an internationally recognized molecular biologist using mouse models of retinal development and degeneration. ..
  22. Type II TGF Beta Receptor and RCC Progression
    Alexander Parker; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  23. ROLE OF TGFBETA IN CORNEAL STROMAL WOUND HEALING
    James V Jester; Fiscal Year: 2010
    ....
  24. Targeting BRM as novel model of prostate hyperplasia
    Karen Knudsen; Fiscal Year: 2007
    ..The studies described will establish the utility of this model for analysis of prostate cancer, and reveal the biological consequence of BRM loss in the prostate. [unreadable] [unreadable] [unreadable]..
  25. Characterization of Methods for Preservation of Phosphoproteins in fixed tissues
    Eric Hsi; Fiscal Year: 2007
    ..Furthermore, control material with defined relative expression levels of many PPs will result from this application and allow laboratories to assess performance of their individual assays. [unreadable] [unreadable] [unreadable]..
  26. International Collaborative HNC Research
    Elaine Smith; Fiscal Year: 2007
    ..This aim is to determine whether there is an easily administered, sensitive biomarker that can predict HPV-HR status in HNC tumors prior to therapy.. [unreadable] [unreadable] [unreadable]..
  27. Epithelial-stromal cell interactions in breast cancer
    Kornelia Polyak; Fiscal Year: 2010
    ....
  28. Transcripitonal and Genetic Profiles in HNSCCs
    Elaine Smith; Fiscal Year: 2008
    ..abstract_text> ..
  29. Effects of Soy on Estrogens in Breast Fluid and Urine
    Gertraud Maskarinec; Fiscal Year: 2010
    ..The NAF approach is the only way to learn more about the beneficial and adverse effects of soy directly in the female breast without applying invasive procedures to women without breast disease or surgery. ..
  30. Aberrant Crypt Foci as a Biomarker for Chemoprevention
    Frank Sinicrope; Fiscal Year: 2009
    ....
  31. Gene Copy Number Changes and Breast Cancer Survival
    Peggy Porter; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  32. Predictive Markers of Glioblastoma Response to VEGF Trap
    John de Groot; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  33. HER2/neu and dietary fat: interactions in breast cancer
    Lisa Yee; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  34. FATTY ACIDS AND PPARS IN BREAST CANCER PREVENTION
    Lisa Yee; Fiscal Year: 2005
    ..Yee the training required to become an independent clinician scientist in the field of preventive oncology. ..
  35. EXERCISE INTERVENTION IN COLORECTAL POLYP PATIENTS
    Anne McTiernan; Fiscal Year: 2004
    ..Results from this unique human experimental study will provide important information about mechanisms of exercise effects on colon carcinogenesis and about potential ..
  36. TGF BETA AND BRAIN TUMORS
    Jeremy Rich; Fiscal Year: 2002
    ....
  37. CEA BASED VACCINE THERAPY IN PATIENTS WITH ADVANCED CA
    John Marshall; Fiscal Year: 2005
    ..So far, the applicant's experience with the first generation CEA-based vaccines has generated a great deal of excitement, and yet he anticipates even more from the newer vaccine constructs. ..
  38. Prostate Cancer: A Mouse Model Testing 15-Lipoxygenase-1
    Uddhav Kelavkar; Fiscal Year: 2004
    ..abstract_text> ..
  39. Polyamines and Breast Cancer Biology
    Andrea Manni; Fiscal Year: 2005
    ..The ultimate goal of these studies is to identify critical signaling molecules which can be targeted in conjunction with antipolyamine therapy to optimize prevention of metastasis from breast cancer. ..
  40. Development of Digital SNP Analysis in Cancer Detection
    Ie Ming Shih; Fiscal Year: 2005
    ..Thus, the encouraging results from this study will ensure the detection of AI in plasma a promising cancer research direction for further exploration. ..
  41. Cohort Study of Risks for Benign Prostatic Hyperplasia
    Alan Kristal; Fiscal Year: 2005
    ..Results from this study will enhance our understanding of the etiology of symptomatic BPH and could potentially be used to develop new strategies for prevention and control of this very common disease. ..
  42. GENETIC DETERMINANTS OF MULTISTEP ORAL TUMORIGENESIS
    Walter Hittelman; Fiscal Year: 2006
    ..abstract_text> ..
  43. EARLY GENETIC EVENTS IN ASTROCYTOMA FORMATION
    JOHN HENSON; Fiscal Year: 2003
    ..As a way forward to new hypotheses, they will determine genome-wide changes in subsets of LGA patients with good and poor outcomes using comparative genomic hybridization (CGH). ..
  44. MUC4 Mucin and Airway Epithelial Regeneration in COPD
    Judith Voynow; Fiscal Year: 2006
    ..Our ultimate goal is to use information from this project to identify new biologic targets for rational therapies to induce normal airway epithelial proliferation and differentiation following injury. ..
  45. HIN-1,A Novel Putative Breast Tumor Suppressor Gene
    Kornelia Polyak; Fiscal Year: 2006
    ..abstract_text> ..
  46. A Phase II Trial of ACAPHA in Former Smokers with IEN.
    Stephen Lam; Fiscal Year: 2006
    ..It will also provide new information on the use of novel biomarkers as surrogate endpoints for assessing the effect of chemoprevention. ..
  47. REGULATION OF CELL DIFFERENTATION DURING DECIDUALIZATION
    Zuzana Strakova; Fiscal Year: 2002
    ..We anticipate that our ongoing studies will contribute to find therapies to treat endometrial dysfunctions associated with infertility, habitual abortions and/or insufficient placental development. ..
  48. Clinical Significance of Apoptosis in Colon Cancer
    Frank Sinicrope; Fiscal Year: 2006
    ..abstract_text> ..
  49. LIPOSOMAL BCL-2 ANTISENSE THERAPY FOR SOLID TUMORS
    Francisco Esteva; Fiscal Year: 2003
    ..Gabriel Lopez-Berestein (Department of Bioimmunotherapy). M. D. Anderson Cancer Center has the patients and resources necessary for Dr. Esteva to successfully complete this research project. ..
  50. REGULATION OF MUCIN GENE EXPRESSION BY ELASTASE
    Judith Voynow; Fiscal Year: 2003
    ..The ultimate goal is to use information from this project to identify new biologic targets for therapeutic interventions to prevent mucus obstruction in chronic inflammatory airway diseases. ..
  51. Humanized mice for Neuro AIDS
    Larisa Poluektova; Fiscal Year: 2008
    ..This model will be the best suited for NeuroAIDS research. [unreadable] [unreadable] [unreadable]..
  52. CHEMOPREVENTION FOR WOMEN AT HIGH RISK OF BREAST CANCER
    CAROL FABIAN; Fiscal Year: 2003
    ..The answer impacts on the entire future of breast cancer chemoprevention development efforts. ..
  53. Prognostic Markers for Juvenile Pilocytic Astrocytomas
    Kwong Kwok Wong; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  54. KERATOCYTE CRYSTALLIN PROTEINS AND CORNEAL TRANSPARENCY
    JAMES JESTER; Fiscal Year: 2003
    ....
  55. Radiation, Hormones & Antisense Prostate Cancer Therapy
    Alan Pollack; Fiscal Year: 2007
    ..abstract_text> ..
  56. CYCLIN E EXPRESSION IN HUMAN CANCER
    Peggy Porter; Fiscal Year: 2002
    ..abstract_text> ..
  57. Hepatocyte growth factor activator and its inhibitors in mouse uterus
    Xuan Zhang; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  58. Changes in Tumor DNA Methylation with Decitabine
    David Stewart; Fiscal Year: 2006
    ..This preliminary look at individual genes may provide a molecular rationale for future decitabine therapeutic studies in specific relevant tumor types. ..
  59. Inflammatory Markers in a 2-Year Soy Intervention among Premenopausal Women
    Gertraud Maskarinec; Fiscal Year: 2008
    ..The statistical analysis will apply general linear models to compare the levels of inflammatory markers by soy intake, while taking into account the repeated measurement design. [unreadable] [unreadable] [unreadable] [unreadable]..
  60. Nutritional Risk Factors for Type 2 Diabetes in the Multiethnic Cohort
    Gertraud Maskarinec; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  61. Breast Density, IGF-I, & Prolactin, in Four Populations
    Gertraud Maskarinec; Fiscal Year: 2004
    ..The statistical analysis will include mixed models to explore the relation between hormone levels and breast density while controlling for confounders and for clustering by study location. ..
  62. AIDS MALIGNANCY CONSORTIUM
    Joseph Sparano; Fiscal Year: 2005
    ..abstract_text> ..
  63. Soy Consumption and Breast Tissue Proliferation
    Gertraud Maskarinec; Fiscal Year: 2006
    ....
  64. NESTED CASE CONTROL STUDY OF MAMMOGRAPHIC DENSITY
    Gertraud Maskarinec; Fiscal Year: 2002
    ....